Skip to main content

Table 1 The general characteristics of NMOSD patients

From: Relationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders

Variable

Patients (n = 32)

Mean Age of onset, year

33.28 (15–62)

Sex (n%)

 Female

30 (93.75%)

 Male

2 (6.25%)

Mean BMI

24.17 (17.57–31.65)

Mean Disease duration, months

85.56 (19–266)

Mean Duration of AZA therapy, months

21.50 (12–40)

Clinical symptoms at onset (n%)

 Optic neuritis

21 (65.6%)

 Bilateral Optic neuritis

17 (53.13%)

 Myelitis

29 (90.6%)

 Optic neuritis and Myelitis

19 (59.3%)

Mean Pre-therapy EDSS score

5.21 ± 0.24 (2.5–8)

Mean Post- therapy EDSS score

2.57 ± 0.33 (0–7)

Mean Concentration of CSF protein, mg/dl

40.41 ± 32.67 (12–184)

Mean Concentration of CSF IgG, mg/ml

0.04 ± 0.03 (0.01–0.19)

CSF IgG index (n%)

0.53 ± 0.10 (0.39–0.83)

Serum anti-AQP4 antibodies (n%)

14 (43.75%)

Mean Concentration of 6-TGNs, pmol/8 × 108 RBC

202.03

Mean Concentration of MMPNs, pmol/8 × 108 RBC

1618.90

Relapse, n%

12/32 (37.5%)

Pre- therapy ARR

1.42 ± 0.23 (0.2–3.5)

Post- therapy ARR

0.36 ± 0.09 (0–1.72)

  1. NMOSD Neuromyelitisoptica spectrum disorders, AZA Azathioprine, AQP4 anti-aquaporin 4, BMI Body mass index, ARR Annual relapse rate, EDSS Expanded disability status scale, CSF cerebrospinal fluid, IgG Immunoglobulin G